$PCMC
PUBLIC CO MANAGEMENT CORP

2023 Q4 Form 10-Q Financial Statement

#000121465924003102 Filed on February 20, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2022 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.890K $5.040K
YoY Change 76.39%
% of Gross Profit
Research & Development $0.00 $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $8.891K $5.039K
YoY Change 76.44% 1159.75%
Operating Profit -$8.891K -$5.039K
YoY Change 76.44% 1159.75%
Interest Expense $2.625K $2.625K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$2.625K -$2.625K
YoY Change 0.0% 0.0%
Pretax Income -$11.52K -$7.660K
YoY Change 50.39%
Income Tax
% Of Pretax Income
Net Earnings -$11.52K -$7.664K
YoY Change 50.26% 153.36%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 34.28M shares 34.28M shares
Diluted Shares Outstanding 34.28M shares 34.28M shares

Balance Sheet

Concept 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.57K $3.410K
YoY Change 1382.99%
Cash & Equivalents $50.57K $3.406K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $50.57K $3.410K
YoY Change 1382.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$5.00 -$4.00
YoY Change 25.0%
TOTAL ASSETS
Total Short-Term Assets $50.57K $3.410K
Total Long-Term Assets -$5.00 -$4.00
Total Assets $50.57K $3.406K
YoY Change 1384.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $57.75K $56.44K
YoY Change 2.32%
Accrued Expenses $76.15K $65.65K
YoY Change 15.99%
Deferred Revenue
YoY Change
Short-Term Debt $425.0K $350.0K
YoY Change 21.43%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $558.9K $472.1K
YoY Change 18.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $558.9K $472.1K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $558.9K $472.1K
YoY Change 18.39%
SHAREHOLDERS EQUITY
Retained Earnings -$5.562M -$5.523M
YoY Change 0.72%
Common Stock $34.28K $34.28K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$508.3K -$468.7K
YoY Change
Total Liabilities & Shareholders Equity $50.57K $3.406K
YoY Change 1384.59%

Cashflow Statement

Concept 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$11.52K -$7.664K
YoY Change 50.26% 153.36%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$8.201K -$1.042K
YoY Change 687.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$8.201K -$1.042K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$8.201K -$1.042K
YoY Change 687.04%
FREE CASH FLOW
Cash From Operating Activities -$8.201K -$1.042K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001141964
CY2023Q4 us-gaap Revenues
Revenues
usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q4 PCMC Accounts Payables And Accrued Expenses Related Party
AccountsPayablesAndAccruedExpensesRelatedParty
usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q4 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q4 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
000-50098
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
PUBLIC CO MANAGEMENT CORP
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0493734
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
9340 Wilshire Boulevard
CY2023Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
 Suite 203
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Beverly Hills
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90212
CY2023Q4 dei City Area Code
CityAreaCode
310
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
862.1957
CY2023Q4 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q4 dei Trading Symbol
TradingSymbol
PCMC
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Cash
Cash
50565 usd
CY2023Q3 us-gaap Cash
Cash
58766 usd
CY2023Q4 us-gaap Assets
Assets
50565 usd
CY2023Q3 us-gaap Assets
Assets
58766 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
12522 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11832 usd
CY2023Q4 PCMC Accounts Payable And Accrued Expenses Related Party
AccountsPayableAndAccruedExpensesRelatedParty
45232 usd
CY2023Q3 PCMC Accounts Payable And Accrued Expenses Related Party
AccountsPayableAndAccruedExpensesRelatedParty
45232 usd
CY2023Q4 PCMC Shortterm Payables
ShorttermPayables
75000 usd
CY2023Q3 PCMC Shortterm Payables
ShorttermPayables
75000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
76154 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
73529 usd
CY2023Q4 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q3 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
558908 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
555593 usd
CY2023Q4 us-gaap Liabilities
Liabilities
558908 usd
CY2023Q3 us-gaap Liabilities
Liabilities
555593 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34276816 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34276816 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
34277 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
34277 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5019739 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5019739 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5562359 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5550843 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-508343 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-496827 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50565 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58766 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8891 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5039 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
8891 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5039 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8891 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5039 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
2625 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
2625 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2625 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2625 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11516 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-7664 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34276816 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34276816 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34276816 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34276816 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-496827 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-11516 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-508343 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-461019 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-7664 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-468683 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-11516 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-7664 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
690 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1025 usd
CY2022Q4 PCMC Accounts Payables And Accrued Expenses Related Party
AccountsPayablesAndAccruedExpensesRelatedParty
2972 usd
CY2023Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2625 usd
CY2022Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2625 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8201 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1042 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8201 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1042 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58766 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4448 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50565 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3406 usd
CY2023Q4 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_840_eus-gaap--NatureOfOperations_zdC9kWxEQ3l9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zK0b3fJ2KACb">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Public Company Management Corporation ("Company”), a Nevada corporation, was formed on October 26, 2000. On October 1, 2004, MyOffiz, Inc. ("MyOffiz") entered into an Exchange Agreement with the certain controlling shareholders of GoPublicToday.com, Inc., Pubco WhitePapers, Inc., and Public Company Management Services, Inc. The Company was the holding company for, and conducted its operations through, its subsidiary companies. The terms "we" and "our" refers to the Company and its subsidiaries unless otherwise stated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Pursuant to the Exchange Agreement, MyOffiz acquired approximately <span id="xdx_908_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_c20231231__us-gaap--BusinessAcquisitionAxis__custom--MyOffizMember_zO990PTfbFih" title="Percentage acquired">92.1%</span> of the outstanding shares of GoPublicToday.com, Inc., all of the outstanding shares of Pubco WhitePapers, Inc., and all of the outstanding shares of Public Company Management Services, Inc in exchange for the new issuance of an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__srt--CounterpartyNameAxis__custom--MyOffizMember_pdd" title="Number of common stock issued during the period">15,326,650</span> of MyOffiz's common stock. Subsequent to the Exchange Agreement, MyOffiz obtained 100% of the partially owned subsidiaries, changed its fiscal year end from June 30 to September 30, and changed its name to Public Company Management Corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">The Company was a management consulting firm that educated and assisted small businesses to improve their management, corporate governance, regulatory compliance, and other business processes, with a focus on capital market participation. The Company offered the following services to its clients at various stages of the business lifecycle:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 50px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Educational products to improve business processes or explore entering the capital markets;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 50px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Startup consulting to early-stage companies planning for growth;</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 50px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management consulting to companies seeking to enter the capital markets via self-underwriting or direct public offering or to move from one capital market to another; and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 50px"><span style="font-family: Symbol; font-size: 10pt">·</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance services to fully reporting, publicly traded companies.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0.05in; margin-bottom: 0pt; text-align: left">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">The Company generated revenues primarily from consulting services that it provided to private company clients seeking to become fully reporting, publicly traded companies. The Company also generated revenue from regulatory compliance services that the Company was providing to public company clients that are required to file periodic and other reports with the Securities and Exchange Commission (“SEC”). The Company would be paid a flat fee for these services, which generally consisted of cash and restricted shares of the Company’s clients’ common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">Predicated upon the economic recession of 2008, commencing with the subprime mortgage crisis and bank crisis, a significant increase in housing foreclosures ultimately caused the stock market to crash in September 2008. At that time, and prior, the Company faced competition from a large number of consulting firms, investment banks, venture capitalists, merchant banks, financial advisors, and other similar management consulting and regulatory compliance services firms. Due to (i) the inability to raise funds in the marketplace and (ii) the intense competition in every aspect of the Company’s business, the Company was unable to operate profitably.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zpFYFHAuRUUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86A_zJ1Zqb7HWBil">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions by management in determining the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates are primarily used in our revenue recognition, long-lived asset impairments and adjustments, deferred tax, stock-based compensation, and reserves for legal matters. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2023Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022Q4 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11516 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7664 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-11516 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-7664 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34276816 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34276816 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34276816 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 PCMC Related Party Transactions Policytext Block
RelatedPartyTransactionsPolicytextBlock
<p id="xdx_84C_ecustom--RelatedPartyTransactionsPolicytextBlock_zccDXEJyCEvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"><b><span id="xdx_867_zOdKIN0wpdTh">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions. Related party note and interest balances as of December 31, 2023 and September 30, 2023 were <span id="xdx_903_ecustom--RelatedPartyNoteAndInterestBalances_c20231231_pp0p0" title="Related party note and interest balances">$426,154</span> and <span id="xdx_90D_ecustom--RelatedPartyNoteAndInterestBalances_iI_pp0p0_c20230930_zLFnMmbaoQzb" title="Related party note and interest balances">$423,529</span>, respectively and related party accrued liabilities as of December 31, 2023 and September 30, 2023 of <span id="xdx_908_ecustom--RelatedPartyAccruedLiabilities_c20231231_pp0p0" title="Related party accrued liabilities">$45,232</span> and <span id="xdx_90D_ecustom--RelatedPartyAccruedLiabilities_iI_pp0p0_c20230930_zZZhDbEonctl" title="Related party accrued liabilities">$45,232</span>, respectively (see Note 4. Related Party Transactions).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q4 PCMC Related Party Note And Interest Balances
RelatedPartyNoteAndInterestBalances
426154 usd
CY2023Q3 PCMC Related Party Note And Interest Balances
RelatedPartyNoteAndInterestBalances
423529 usd
CY2023Q4 PCMC Related Party Accrued Liabilities
RelatedPartyAccruedLiabilities
45232 usd
CY2023Q3 PCMC Related Party Accrued Liabilities
RelatedPartyAccruedLiabilities
45232 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q4 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2022Q4 us-gaap Advertising Expense
AdvertisingExpense
0 usd
CY2023Q4 us-gaap Depreciation
Depreciation
0 usd
CY2022Q4 us-gaap Depreciation
Depreciation
0 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5562359 usd
CY2023Q4 PCMC Working Capital Deficit
WorkingCapitalDeficit
508343 usd
CY2023Q4 PCMC Shortterm Payables
ShorttermPayables
75000 usd
CY2023Q3 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
2625 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
2625 usd
CY2023Q4 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q3 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
76154 usd
CY2023Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
73529 usd
CY2023Q4 PCMC Note Payable Related Party
NotePayableRelatedParty
350000 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
76154 usd
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
65654 usd
CY2023Q4 PCMC Due To Related Party
DueToRelatedParty
45232 usd
CY2023Q3 PCMC Due To Related Party
DueToRelatedParty
45232 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34276816 shares
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2022Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2023Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
5562359 usd
CY2023Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
5550843 usd
CY2023Q4 PCMC Offset Income
OffsetIncome
106167 usd

Files In Submission

Name View Source Status
0001214659-24-003102-index-headers.html Edgar Link pending
0001214659-24-003102-index.html Edgar Link pending
0001214659-24-003102.txt Edgar Link pending
0001214659-24-003102-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pcmc-20231231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
r21424010q.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pcmc-20231231_cal.xml Edgar Link unprocessable
pcmc-20231231_lab.xml Edgar Link unprocessable
pcmc-20231231_pre.xml Edgar Link unprocessable
r21424010q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
pcmc-20231231_def.xml Edgar Link unprocessable